IFRX InflaRx GmbH: רווח נקי למניה ב-12 החודשים האחרונים

InflaRx N.V. (IFRX) management leverages its expertise in inflammation therapy to develop unique antibodies for combating systemic pathologies. The stock price history reflects the EPS TTM trend, which currently stands at -40.60. However, a narrow development pipeline and the costs associated with Vilobelimab trials create financial risks. The company's environmental policy is limited to standard waste disposal and wastewater treatment in its laboratories.

Investment risks for InflaRx N.V. (IFRX) are determined by the company's ability to convert antibody development costs into actual profit, as reflected in the year-over-year EPS dynamics (trailing 12 months). This indicator measures the growth rate of net income per share over a rolling year, allowing for an assessment of R&D monetization efficiency amid tight monetary policy and high interest rate pressure.